XML 57 R45.htm IDEA: XBRL DOCUMENT v3.22.0.1
License Agreements - Novartis (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended 146 Months Ended
Apr. 30, 2016
Nov. 30, 2009
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2021
License agreements            
Revenues     $ 2,986,267 $ 2,666,702 $ 2,158,759  
U.S.            
License agreements            
Revenues     2,900,000 2,600,000 2,100,000  
Europe            
License agreements            
Revenues     124,100 105,000 90,000  
JAKAFI            
License agreements            
Revenues     2,134,508 1,937,850 1,684,968  
Novartis            
License agreements            
Revenues     0 170,000 0  
Novartis | Development Milestones            
License agreements            
Amount recognized and received for the achievement of a predefined milestone           $ 157,000
Novartis | Development Milestones | Maximum            
License agreements            
Upfront and immediate milestone payment to be received under license agreement   $ 174,000        
Novartis | Regulatory Milestones            
License agreements            
Amount recognized and received for the achievement of a predefined milestone           280,000
Novartis | Regulatory Milestones | Maximum            
License agreements            
Upfront and immediate milestone payment to be received under license agreement   495,000        
Novartis | Commercialization Milestones            
License agreements            
Amount recognized and received for the achievement of a predefined milestone           200,000
Novartis | Commercialization Milestones | Maximum            
License agreements            
Upfront and immediate milestone payment to be received under license agreement   $ 500,000        
Novartis | TABRECTA            
License agreements            
Revenues     10,400 4,100    
Novartis | TABRECTA | Development Milestones            
License agreements            
Amount recognized and received for the achievement of a predefined milestone       25,000    
Novartis | TABRECTA | Regulatory Milestones            
License agreements            
Amount recognized and received for the achievement of a predefined milestone       45,000    
Novartis | TABRECTA | Regulatory Milestones | Japan            
License agreements            
Amount recognized and received for the achievement of a predefined milestone       20,000    
Novartis | GVHD | Development and Regulatory Milestones | Maximum            
License agreements            
Upfront and immediate milestone payment to be received under license agreement $ 75,000          
Novartis | JAKAFI | U.S.            
License agreements            
Revenues     99,600 89,900 77,600  
Royalties payable     148,100 96,400   $ 148,100
Novartis | JAKAVI            
License agreements            
Revenues     $ 338,000 $ 277,900 $ 225,900  
Novartis | JAKAVI | Minimum            
License agreements            
Royalty payments on future global net sales (as a percent)     12.00%      
Novartis | JAKAVI | Maximum            
License agreements            
Royalty payments on future global net sales (as a percent)     14.00%      
Novartis | JAKAVI | Commercialization Milestones            
License agreements            
Amount recognized and received for the achievement of a predefined milestone     $ 80,000      
Revenues     $ 1,200,000